Experiment Protocol Biomedical Engineer in France Paris –Free Word Template Download with AI

This Experiment Protocol outlines the methodology for the clinical validation of a novel non-invasive wearable biosensor designed for continuous glucose monitoring (CGM). As a Biomedical Engineer operating within the regulatory framework of France, specifically in Paris, this research aims to bridge the gap between engineering innovation and clinical application. The study will be conducted in collaboration with the Pitié-Salpêtrière Hospital, a leading medical center in Paris, France, ensuring access to a diverse patient population and state-of-the-art medical infrastructure.

The primary objective is to evaluate the accuracy, reliability, and safety of the prototype device against standard invasive blood glucose measurements. This protocol adheres strictly to the ethical guidelines established by the French National Agency for the Safety of Medicines and Health Products (ANSM) and the European Union Medical Device Regulation (EU MDR 2017/745).

Primary Objective:

To determine the Mean Absolute Relative Difference (MARD) between glucose values obtained from the wearable biosensor and reference laboratory measurements.

Secondary Objectives:

• To assess the device's response time to rapid glucose fluctuations.
• To evaluate user comfort and skin compatibility over a 14-day wear period.
• To analyze the signal stability under various environmental conditions typical of Paris, France (e.g., humidity, temperature variations).

This is a prospective, single-arm, open-label clinical study. The study will recruit 50 adult participants diagnosed with Type 1 or Type 2 diabetes. The study duration for each participant will be 14 days. The Biomedical Engineer team will oversee the device calibration, data acquisition, and technical troubleshooting throughout the study period.

5.1 Device Application:

Upon enrollment, the Biomedical Engineer will apply the wearable biosensor to the participant's upper arm. The site will be cleaned with an alcohol swab, and the sensor will be secured using a hypoallergenic adhesive patch. The device will be calibrated using a finger-stick blood glucose meter provided by the study team.

5.2 Data Collection:

Participants will wear the device continuously for 14 days, removing it only for showering (if the device is not waterproof) or as instructed. They will record finger-stick blood glucose measurements four times daily (before meals and at bedtime) and whenever they feel hypoglycemic or hyperglycemic symptoms. These reference values will be logged in a study diary and uploaded to a secure cloud platform compliant with French data protection laws (RGPD/GDPR).

5.3 Follow-up Visits:

Participants will attend two follow-up visits at the Paris research site: one at day 7 and one at day 14. During these visits, the Biomedical Engineer will inspect the sensor site for irritation, download device data, and address any technical issues.

The primary endpoint, MARD, will be calculated using the formula:

MARD = (1/N) * Σ |(Sensor Value - Reference Value) / Reference Value| * 100%

A MARD value of less than 10% will be considered acceptable for clinical use. Additional analyses will include Clarke Error Grid Analysis and Parkes Error Grid Analysis to assess clinical accuracy. Statistical analysis will be performed using R software, with a significance level set at p < 0.05.

This study has been reviewed and approved by the Ethics Committee of the Pitié-Salpêtrière Hospital in Paris, France. All procedures will be conducted in accordance with the Declaration of Helsinki. Informed consent will be obtained from all participants prior to any study-related procedures. Data privacy will be maintained in compliance with the French Data Protection Act (Loi Informatique et Libertés) and the General Data Protection Regulation (GDPR).

The Biomedical Engineer team is responsible for ensuring that all devices meet the safety standards required by the ANSM. Any adverse events related to the device will be reported immediately to the Ethics Committee and the ANSM.

Potential risks include skin irritation at the sensor site, inaccurate glucose readings leading to inappropriate insulin dosing, and data privacy breaches. To mitigate these risks:

• Participants will be instructed to monitor their skin and report any irritation immediately.
• Participants will be advised not to rely solely on the wearable sensor for insulin dosing decisions during the study period.
• All data will be encrypted and stored on secure servers located in France.

This Experiment Protocol provides a comprehensive framework for the clinical validation of a novel wearable biosensor in Paris, France. By adhering to rigorous scientific and ethical standards, this study aims to contribute to the advancement of biomedical engineering and improve the quality of life for individuals with diabetes. The insights gained from this research will inform future iterations of the device and support its regulatory approval for commercial use in Europe.